Citations

Clear

313 citation(s) found for "Alvarez, P".

Endoscopic Endonasal Transcavernous Hemipituitary Transposition for Resection of Invasive Prolactinoma: 2-Dimensional Operative Video
Caicedo, Diana C. Alvarez , Donaldson, Angela M. , Samson, Susan L. , Chaichana, Kaisorn L. , Almeida, João Paulo , Alvarez Caicedo, Diana C, Almeida, Joao Paulo

Mayo Clinic

Operative Neurosurgery | February 1, 2024 | Volume: 27 | Issue: 1 | Pages: 129-130

10.1227/ons.0000000000001075 | PMID 38299803 Get It

HOCl-producing electrochemical bandage for treating Pseudomonas aeruginosa -infected murine wounds
Fleming, Derek , Bozyel, Ibrahim , Ozdemir, Dilara , Otero, Judith Álvarez , Karau, Melissa J. , Anoy, Md Monzurul Islam , Koscianski, Christina, Schuetz, Audrey N. , Greenwood‐Quaintance, Kerryl E. , Mandrekar, Jayawant N. , Patel, Robin , Schuetz, Audrey N , Fleming, Derek , Beyenal, Haluk , Patel, Robin

Mayo Clinic

Antimicrobial Agents and Chemotherapy | January 12, 2024 | Volume: 68 | Issue: 2 | Pages: No page available

10.1128/aac.01216-23 | PMID 38214514 Get It

ABSTRACT The growing threat of antibiotic-resistant bacterial pathogens necessitates the development of alternative antimicrobial approaches. This is particularly true for chronic wound infections, which commonly harbor biofilm-dwelling bacteria. A novel electrochemical bandage (e-bandage) delivering low-levels of hypochlorous acid (HOCl) was evaluated against Pseudomonas aeruginosa murine wound biofilms. 5 mm skin wounds were created on the dorsum of mice and infected with 10 6 colony-forming units (CFU) of P. aeruginosa . Biofilms were formed over 2 days, after which e-bandages were placed on the wound beds and covered with Tegaderm. Mice were administered Tegaderm-only (control), non-polarized e-bandage (no HOCl production), or polarized e-bandage (using an HOCl-producing potentiostat), with or without systemic amikacin. Purulence and wound areas were measured before and after treatment. After 48 hours, wounds were harvested for bacterial quantification. Forty-eight hours of polarized e-bandage treatment resulted in mean biofilm reductions of 1.4 log 10 CFUs/g ( P = 0.0107) vs non-polarized controls and 2.2 log 10 CFU/g ( P = 0.004) vs Tegaderm-only controls. Amikacin improved CFU reduction in Tegaderm-only ( P = 0.0045) and non-polarized control groups ( P = 0.0312) but not in the polarized group ( P = 0.3876). Compared to the Tegaderm-only group, there was less purulence in the polarized group ( P = 0.009). Wound closure was neither impeded nor improved by either polarized or non-polarized e-bandage treatment. Concurrent amikacin did not impact wound closure or purulence. In conclusion, an HOCl-producing e-bandage reduced P. aeruginosa in wound biofilms with no impairment in wound healing, representing a promising antibiotic-free approach for addressing wound infection.
Rejection Requiring Treatment within the First Year following Heart Transplantation: The UNOS Insight
Gemelli, Marco , Doulamis, Ilias P. , Tzani, Aspasia , Rempakos, Athanasios, Guariento, Alvise , Spiliopoulos, Kyriakos , Asleh, Rabea , Duque, Ernesto Ruiz , Briasoulis, Αlexandros , Guariento, Alvise , Spiliopoulos, Kyriakos , Asleh, Rabea , Duque, Ernesto Ruiz , Briasoulis, Alexandros , Kampaktsis, Polydoros Ν. , Álvarez, Paulino , Xanthopoulos, Andrew V. , Giamouzis, Grigorios

Mayo Clinic

Journal of Personalized Medicine | December 29, 2023 | Volume: 14 | Issue: 1 | Pages: 52

10.3390/jpm14010052 | PMID 38248753 Get It

(1) Background: Heart failure is an extremely impactful health issue from both a social and quality-of-life point of view and the rate of patients with this condition is destined to rise in the next few years. Transplantation remains the mainstay of treatment for end-stage heart failure, but a shortage of organs represents a significant problem that prolongs time spent on the waiting list. In view of this, the selection of donor and recipient must be extremely meticulous, considering all factors that could predispose to organ failure. One of the main considerations regarding heart transplants is the risk of graft rejection and the need for immunosuppression therapy to mitigate that risk. In this study, we aimed to assess the characteristics of patients who need immunosuppression treatment for rejection within one year of heart transplantation and its impact on mid-term and long-term mortality. (2) Methods: The United Network for Organ Sharing (UNOS) Registry was queried to identify patients who solely underwent a heart transplant in the US between 2000 and 2021. Patients were divided into two groups according to the need for anti-rejection treatment within one year of heart transplantation. Patients’ characteristics in the two groups were assessed, and 1 year and 10 year mortality rates were compared. (3) Results: A total of 43,763 patients underwent isolated heart transplantation in the study period, and 9946 (22.7%) needed anti-rejection treatment in the first year. Patients who required treatment for rejection within one year after transplant were more frequently younger (49 ± 14 vs. 52 ± 14 years, p < 0.001), women (31% vs. 23%, p < 0.001), and had a higher CPRA value (14 ± 26 vs. 11 ± 23, p < 0.001). Also, the rate of prior cardiac surgery was more than double in this group (27% vs. 12%, p < 0.001), while prior LVAD (12% vs. 11%, p < 0.001) and IABP (10% vs. 9%, p < 0.01) were more frequent in patients who did not receive anti-rejection treatment in the first year. Finally, pre-transplantation creatinine was significantly higher in patients who did not need treatment for rejection in the first year (1.4 vs. 1.3, p < 0.01). Most patients who did not require anti-rejection treatment underwent heart transplantation during the new allocation era, while less than half of the patients who required treatment underwent transplantation after the new allocation policy implementation (65% vs. 49%, p < 0.001). Patients who needed rejection treatment in the first year had a higher risk of unadjusted 1 year (HR: 2.25; 95% CI: 1.88–2.70; p < 0.001), 5 year (HR: 1.69; 95% CI: 1.60–1.79; p < 0.001), and 10 year (HR: 1.47; 95% CI: 1.41–1.54, p < 0.001) mortality, and this was confirmed at the adjusted analysis at all three time-points. (4) Conclusions: Medical treatment of acute rejection was associated with significantly increased 1 year mortality compared to patients who did not require anti-rejection therapy. The higher risk of mortality was confirmed at a 10 year follow-up. Further studies and newer follow-up data are required to investigate the role of anti-rejection therapy in the heart transplant population.
Structural variants in Lewy body dementia and frontotemporal dementia spectrum
Ding, Jinhui , Rasheed, Memoona, Walton, Ronald L., Brand, Harrison , Zhao, Xuefang , Dewan, Ramita , Solaiman, Sultana , Dawson, Ted M. , Albert, Marilyn S. , Pletnikova, Olga, Troncoso, Juan C. , Masellis, Mario, Keith, Julia , Resnick, Susan M. , Ryten, Mina , Hardy, John , Mazzini, Letizia , Moglia, Cristina, Beach, Thomas G. , Graff‐Radford, Neill R. , Jager, Philip L. De , Hardy, John , Kaivola, Karri , Chia, Ruth , Fujita, Masashi , Menon, Vilas , Collins, Ryan L. , Billingsley, Kimberley J. , Talkowski, Michael E. , Ray, Anindita , Jerez, Pilar Álvarez , Malik, Laksh , Rosenthal, Liana S. , Pletniková, Olga , Black, Sandra E. , Ferrucci, Luigi , Tanaka, Toshiko , Topol, Eric J. , Torkamani, Ali , Tienari, Pentti J. , Foroud, Tatiana , Ghetti, Bernardino , Landers, John E. , Morris, Huw R. , D’Alfonso, Sandra , Moglia, Cristina , Calvo, Andrea , Serrano, Geidy E. , Ferman, Tanis J. , Boeve, Bradley F. , Wszołek, Zbigniew K. , Dickson, Dennis W. , Chiò, Adriano , Bennett, David A. , Ross, Owen A. , Dalgard, Clifton L. , Gibbs, J. Raphael , Traynor, Bryan J. , Scholz, Sonja W.

Mayo Clinic

Alzheimer's & Dementia | December 25, 2023 | Volume: 19 | Issue: S12 | Pages: No page available

10.1002/alz.078497 Get It

AbstractBackgroundStructural variants range from simple loss or gain of genetic material to complex events that restructure entire chromosomes. This heterogeneity coupled with variant size greater than sequencing read‐length makes structural variant mapping from short‐read sequencing data difficult and error‐prone. Consequently, the role of structural variants is poorly explored in many phenotypes, including dementia.MethodWe used the GATK‐SV pipeline that combines four external structural variant mapping algorithms with machine‐learning to build high‐quality consensus structural variant calls. We applied GATK‐SV to short‐read whole‐genome sequencing data of 2,601 frontotemporal dementia‐amyotrophic lateral sclerosis spectrum (FTD/ALS) patients, 2,612 Lewy body dementia (LBD) patients, and 4,132 neurologically unaffected participants.ResultAfter stringent quality‐control, we performed genome‐wide association studies on 2,307 ALS/FTD patients versus 3,677 controls with 4,699 common structural variants and 2,355 LBD patients versus 3,700 controls with 4,889 common structural variants. In the FTD/ALS cohort, we identified well‐known risk variants at the C9orf72 (p‐value = 4.99×10‐18, OR = 14.47, 95% CI = 7.90–26.49) and MAPT loci (p‐value = 3.48×10‐6, OR = 0.77, 95% CI = 0.68–0.86) corroborating the ability of our pipeline to identify disease‐associated structural variants. Moreover, we discovered, replicated, and validated TPCN1 as a novel risk locus for LBD (p‐value = 9.18×10‐6, OR = 1.43, 95% CI = 1.22–1.67). Further, we identified rare exonic variants with known pathogenic or likely pathogenic effects, such as an SNCA gene duplication in LBD and a deletion of exons 1 and 2 in CHCHD10 in FTD/ALS. We additionally observed structural variants in regulatory regions, e.g. a deletion of a key PSEN2 enhancer, which resulted in an approximate 0.70 fold‐change in PSEN2 expression in LBD. Finally, we built an interactive web app where structural variants can be visualized and explored (https://ndru-ndrs-lng-nih.shinyapps.io/non_ad_dementias_sv_app/).ConclusionCommon and rare structural variants play a role in LBD and FTD/ALS. Our structural variant resource is publicly available and can be used to further explore the role of structural variants in LBD and FTD/ALS.
Abstract 18629: Discriminative Accuracy of Cha 2 Ds 2 Vasc Score, and Development of Predictive Accuracy Model Using Machine Learning for Ischemic Stroke in Cardiac Amyloidosis
Ullah, Waqas , Nair, Abhinav , Warner, Eric, Rajapreyar, Indranee, Alvarez, René , Yaddanapudi, Sridhara , Maurer, Mathew S. , Brailovsky, Yevgeniy , Brailovsky, Yevgeniy , Zahid, Salman , Frisch, Daniel R. , Rajapreyar, Indranee N. , Alkhouli, Mohamad , Maurer, Mathew S

Mayo Clinic

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.18629 Get It

Background: Cardiac amyloidosis (CA) in conjunction with atrial fibrillation (AF) presents unique management challenges. CHA2DS2VASc score in these patients is believed to underestimate the risk of ischemic stroke, necessitating a better predictive model in these patients. Methods: Data was obtained from the National Readmission Database (NRD). Outcomes between CA-AF and no-CA-AF were compared using multivariate regression analysis to calculate adjusted odds ratios (aOR). AutoScore; an interpretable machine learning framework, was used to develop a stroke risk prediction model, the predictive accuracy of which was evaluated with an area under the curve (AUC) using the receiver operating characteristic analysis. Results: A total of 11,860,804 (CA-AF 22,687 [0.19%] and no-CA-AF 11,838,117) patients were identified from 2015-2019. The adjusted odds of mortality (aOR 1.41 and 1.29), stroke (aOR 1.78 and 1.74), non-intracranial hemorrhage (aOR 2.10 and aOR 1.85), and intracranial hemorrhage (aOR 14.4 and aOR 4.26) were significantly higher in CA-AF compared with non-CA-AF at both index admission and 30-days, respectively. The CHA 2 DS 2 VASc score had a poor discriminative accuracy for stroke at 30-days in CA-AF (AUC 49%, 95%CI 47%-51%, p=0.54). The machine learning autoscore integrative model revealed that the predictive ability of our newly proposed E-CHADS score (end-stage renal disease (ESRD), congestive heart failure, hypertension, active cancer, dementia, and diabetes mellitus) for 30-day risk of ischemic stroke in CA-AF was excellent (for a cutoff of 52 points random forest score) with an AUC of 80% (95%CI 74%-86%) Conclusion: Cardiac amyloidosis carries a high risk of ischemic stroke that is not accurately predicted by the CHA 2 DS 2 VASc score. Our proposed model (E-CHADS) identifies 3 new variables (ESRD, dementia, and cancer) that have higher discriminative accuracy for ischemic stroke in these patients.
Abstract 12686: Serious Complications Occur in Patients With Transcatheter Aortic Valve Replacement Who Develop In-Hospital Infective Endocarditis
Martinez, Juan A Quintero, Vásquez, Moisés, Mintz, Joel A. , Iskander, Mina , Luna-Álvarez-Amezquita, José Antonio , Noy, Jose, Uribe, Juan S. , Espinoza, Joaquin , Lecompte-Osorio, P.A. , Marchena, Eduardo de , Mintz, Joel, mustafa, mohammed, Alfonso, Carlos, Baddour, Larry M.

Mayo Clinic

Circulation | December 19, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.12686 Get It

Introduction: Transcatheter aortic valve replacement (TAVR) is a well-recognized treatment for severe aortic stenosis. One potentially life-threatening complication of TAVR is infective endocarditis (IE). There is limited contemporary data on the clinical characteristics and outcomes of patients undergoing TAVR who develop in-hospital IE. Aim: Describe the clinical characteristics and outcomes of patients undergoing TAVR who develop in-hospital IE. Methods: The National Inpatient Sample Database was queried from 2016 to 2020 for relevant ICD-10 procedural and diagnostic codes. Baseline characteristics and in-hospital outcomes of adult (≥18 years) patients undergoing TAVR who developed in-hospital IE were compared to that of patients who did not develop IE. Multivariate logistic-regression analyses adjusting for age, race, gender, and statistically significant comorbidities between cohort's were performed. A p-value <0.05 was considered significant. Results: A total of 314,250 hospitalizations for patients undergoing TAVR were identified. Of them, 1065 (0.3%) developed in-hospital IE. Overall, mean age of IE patients was 70.3 ± 15.0. Patients were predominantly (62%) males and white (79.5%) ( Table 1) . IE patients had a higher risk of in-hospital all-cause mortality (adjusted odds ratio [95% CI]: 2.07 [1.50-2.86]), septic shock (3.73 [2.71-5.13]), acute respiratory failure (2.59 [2.19-3.06]), ischemic stroke (4.4 [3.48-5.51]), acute kidney injury (3.05 [2.61-3.57]), cardiac arrest (2.82 [1.83-4.37] and cardiogenic shock 3.70 [2.98-4.57]). All p values were <0.01. Conclusion: Patients undergoing TAVR who develop in-hospital IE had higher in-hospital complications when compared to those of patients who did not develop IE. Although the rate of in-hospital IE was low, the number of patients identified in the NIS database was sizable and the syndrome deserves investigation due to its associated complications.
The Effect of Adding Physician Recommendation in Digitally-Enabled Outreach for COVID-19 Vaccination in Socially/Economically Disadvantaged Populations Subtitle: A Randomized Controlled Trial
Sumar, Kamal, Blue, Lisa, Fatahi, Gina, Bhatti, Atiq ur Rehman , Sumar, Mehek, Alvarez, Stéphanie, Cons, Pedro, Valencia, Nathalie, Bhatti, Atiq

Mayo Clinic

No container title available | December 11, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3604972/v1 | PMID 38168293 Get It

Abstract Introduction: People from backgrounds that are economically/socially disadvantaged experienced disproportionately high COVID-19 death rates and had lower vaccination rates. Effective outreach strategies for increasing vaccine uptake during the pandemic are not fully known. Among patients receiving care at a Federally Qualified Health Center, we tested whether community engaged digitally-enabled outreach increased COVID vaccine uptake. Study Design, Setting, and Participants: A 3-parallel-arm randomized controlled trial with a hybrid effectiveness-implementation design was conducted among patients ≥18 years old on study enrollment during 2021 with 1,650 assigned in 3:10:20 ratio; 2,328 were later selected for two subsequent implementation rounds. Interventions: From April 13 to June 10, 2021, patients were proactively sent a text-messaging invitation to make an appointment for vaccination as part of the routine practice (Arm 1, n=150) with added personalized clinician recommendation alone (Arm 2, n=500) or with an explicit nudge for answers to frequently asked questions (Arm 3, n=1,000). Further implementation used messaging addressing vaccine hesitancy (n=1,323) or adverse reactions to vaccines (n=1,005). Main Outcomes and Measures: The primary outcome was the completion of the first SARS-Cov-2 vaccine dose determined at 14, 30 and 90 days after outreach. Results: Of 1,650 patients in effectiveness Arms, 61% was female. Vaccination rates for Arms 1, 2, and 3, were 6% (n=9), 5.4% (n=27) and 3.3% (n=33) at 14 days, and 11.5% (n=17), 11.6% (n=58), and 8.5% (n=85) at 90 days, respectively, which were similar in pairwise comparisons. At 90 days, vaccination rates were similar across the two implementation rounds (3.9% vs. 3.6%) and were similar to the rate (3.3%) among patients who were not selected for intervention arms or implementation rounds (n=8,671). Conclusions: Digitally-enabled outreach that included SMS messaging outreach augmented with clinician recommendations did not improve COVID-19 vaccination rates. Trial Registration: This study is registered at ClinicalTrails.gov Identifier: NC-T04952376
Hormonal Exposures Relate to Clinical Phenotype in Women with Neuromyelitis Optica (S12.005)
Bove, Riley , Elsone, Liene, Borisow, Nadja, Sorum, Jaime, Mutch, Kerry , Tobyne, Sean , Ruprecht, Klemens , Buckle, Guy J., Wingerchuk, Dean M. , Friedemann, Paul, Weinshenker, Brian, Jacob, Anu , Klawiter, Eric C. , Álvarez, Enrique , Cortez, Melissa , Mateen, Farrah J. , Mealy, Maureen A. , Levy, Michael , Friedemann, Paul, Cross, Anne H. , Chitnis, Tanuja

Mayo Clinic

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.s12.005 Get It

Preliminary Results of the NINDS/NIBIB Consensus Meeting to Evaluate Pathological Criteria for the Diagnosis of CTE (P2.178)
McKee, Ann C. , Alvarez, Victor E., Cairns, Nigel J. , Crary, John F. , Folkerth, Rebecca D., Montine, Thomas J. , Montenigro, Philip H. , Perl, Daniel P. , Stewart, William F., Vonsattel, Jean Paul, Gordon, Wayne A., Bieniek, Kevin F. , Dams-O’Connor, Kristen , Keene, C. Dirk , Litvan, Irene , Stein, Thor D. , Stewart, William, Tripodis, Yorghos , Dickson, Dennis W.

Mayo Clinic

Neurology | December 6, 2023 | Volume: 84 | Issue: 14_supplement | Pages: No page available

10.1212/wnl.84.14_supplement.p2.178 Get It